Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa
Abstract Background The introduction of Bedaquiline, the first new antimycobacterial drug in over 40 years, has highlighted the critical importance of medication adherence in drug-resistant tuberculosis (DR-TB) treatment to prevent amplified drug-resistance and derive sustained benefit. Real-time el...
Main Authors: | N. Bionghi, A. Daftary, B. Maharaj, Z. Msibi, K. R. Amico, G. Friedland, C. Orrell, N. Padayatchi, M. R. O’Donnell |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-04-01
|
Series: | BMC Infectious Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12879-018-3080-2 |
Similar Items
-
The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
by: Uzma Khan, et al.
Published: (2019-08-01) -
Cardiac toxicity of fluoroquinolones and bedaquiline
by: G. N. Mozhokinа, et al.
Published: (2019-05-01) -
Bedaquiline: Current status and future perspectives
by: Saeed Khoshnood, et al.
Published: (2021-06-01) -
Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
by: Villellas, C., et al.
Published: (2019) -
Bedaquiline in the treatment regimen of multidrugresistant tuberculosis (clinical observation)
by: V. A. Aksenova, et al.
Published: (2020-11-01)